Intellia Therapeutics cuts 15% of workforce, extends cash runway into mid-2026
Intellia Therapeutics announced Thursday that it is cutting 15% of its workforce and pausing certain research programs following an internal review.
A representative for Intellia told Endpoints News that the company cut positions across all departments, though it won’t impact its lead programs and candidates. The programs that Intellia is ending “would generally be undisclosed targets/projects that were much earlier in the research process,” according to the representative.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.